Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Aug 5.

Published in final edited form as: Clin Chem. 2012 Mar 26;58(6):1010–1018. doi: 10.1373/clinchem.2011.179200

Fig. 4 — Type 1 vWD patients () have a distribution of mean diffusion times that overlaps that of samples with vWF within reference intervals (), but with a significantly reduced effective bound fraction, reflecting reduced amounts of a relatively normal distribution of multimers in type 1 vWD. Type 2 vWD patients have an effective bound fraction component that overlaps that of type 1 vWD patients but with a reduced diffusion time, reflecting a lack of large multimers (). Three samples with high vWF:Ag but abnormal multimer analysis lacking large multimers () show a high effective bound fraction and short mean diffusion time. Two of these samples have been classified clinically as acquired vWD. The type 1 and type 2 vWD samples shown in Fig. 3 are denoted by arrows. The 4-h post-DDAVP sample described in Fig. 5 is also shown for reference ().

Inline graphic — Type 1 vWD patients () have a distribution of mean diffusion times that overlaps that of samples with vWF within reference intervals (), but with a significantly reduced effective bound fraction, reflecting reduced amounts of a relatively normal distribution of multimers in type 1 vWD. Type 2 vWD patients have an effective bound fraction component that overlaps that of type 1 vWD patients but with a reduced diffusion time, reflecting a lack of large multimers (). Three samples with high vWF:Ag but abnormal multimer analysis lacking large multimers () show a high effective bound fraction and short mean diffusion time. Two of these samples have been classified clinically as acquired vWD. The type 1 and type 2 vWD samples shown in Fig. 3 are denoted by arrows. The 4-h post-DDAVP sample described in Fig. 5 is also shown for reference ().